Tokyo, Japan – June 9, 2026
Kyowa Kirin Co., Ltd. has published its Integrated Report 2025, outlining the company’s strategy for sustainable growth, innovation, corporate governance, and long-term value creation as it advances toward its ambitious Vision 2030 roadmap. The report provides investors, stakeholders, and the broader healthcare community with a detailed overview of how the Japan-based global specialty pharmaceutical company plans to strengthen its position in the pharmaceutical industry through innovation, patient-centric value creation, and sustainable business practices. The publication underscores Kyowa Kirin’s commitment to delivering life-changing medicines and treatments while enhancing corporate value and maintaining a strong focus on patients with significant unmet medical needs.
Vision 2030 Drives Long-Term Growth Strategy
At the core of the report is Kyowa Kirin’s vision to evolve into a stronger Global Specialty Pharmaceutical (GSP) company, leveraging decades of expertise in biotechnology, drug discovery, and advanced therapeutic development. The company highlighted its review of the 2021–2025 Medium-Term Business Plan and outlined key strategies designed to achieve Vision 2030. According to the report, leadership is focused on expanding innovation capabilities, strengthening global operations, and delivering sustainable value through both financial and non-financial initiatives. The company’s management emphasized that future growth will be driven by scientific excellence, operational efficiency, and continued investment in breakthrough healthcare solutions. The report also highlights the importance of maintaining strong relationships with shareholders and stakeholders while positioning the organization for the next chapter of its growth journey.
Governance Transformation and Patient-Centric Innovation
A major focus of the Integrated Report 2025 is the evolution of Kyowa Kirin’s corporate governance framework. The company detailed its transition to a Company with an Audit and Supervisory Committee and the introduction of a new C-suite executive structure, initiatives designed to improve transparency, accountability, and strategic decision-making. Alongside governance enhancements, Kyowa Kirin reinforced its commitment to patient-centric value creation, emphasizing research and development efforts that aim to address serious diseases and unmet medical needs. The report highlights how innovation remains a central pillar of the company’s growth strategy, with continued investments in advanced therapeutic technologies and scientific research intended to improve patient outcomes worldwide. By integrating governance excellence with innovation-driven healthcare solutions, the company aims to strengthen its long-term competitiveness in the global pharmaceutical market.
Advertisement
Sustainability and Human Capital Support Future Value Creation
The report further emphasizes the importance of sustainability, organizational development, and human capital as critical enablers of long-term success. Kyowa Kirin outlined initiatives focused on addressing environmental and social challenges while fostering a corporate culture that encourages innovation, diversity, and collaboration. The company believes that sustainable value creation depends not only on scientific advancement but also on empowering employees and building resilient organizational capabilities. As part of its long-term strategy, Kyowa Kirin continues to invest in next-generation technologies, including antibody engineering, cell therapies, and gene therapies targeting rare diseases, hematological disorders, and other areas with significant unmet medical need. Through these efforts, the company aims to contribute to global health and well-being while creating lasting value for patients, healthcare systems, investors, and society.
Source: Kyowa Kirin press release
